Disclaimer
The foregoing release contains certain forward-looking statements that can be
identified by terminology such as “commitment,” “expected,” “plans,” “goal,” or
similar expressions, or by express or implied discussions potential future deliveries of
leprosy MDT drugs or related anti-leprosy services. You should not place undue
reliance on these statements. Such forward-looking statements reflect the current
views of the Company regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially different
from any future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that Novartis will deliver any particular
amounts of MDT or related services in the future. In particular, management's
expectations could be affected by, among other things, unexpected regulatory actions
or delays or government regulation generally; unexpected manufacturing difficulties;
competition in general; government, industry, and general public pricing and other
political pressures; the impact that the foregoing factors could have on the values
attributed to the Novartis Group's assets and liabilities as recorded in the Group's
consolidated balance sheet; and other risks and factors referred to in Novartis AG’s
current Form 20-F on file with the US Securities and Exchange Commission. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those described
herein as anticipated, believed, estimated or expected. Novartis is providing the
information in these materials as of this date and does not undertake any obligation
to update any forward-looking statements as a result of new information, future events
or otherwise.